Enhertu Wins EU Approval After Surgery, Cutting Recurrence Risk 53% — AstraZeneca Owes Daiichi $75 Million

The European Commission cleared the cancer drug for HER2-positive early breast cancer patients with residual disease, triggering a milestone payment.

Share
Enhertu Wins EU Approval After Surgery, Cutting Recurrence Risk 53% — AstraZeneca Owes Daiichi $75 Million

AstraZeneca, the pharmaceutical company behind cancer drugs including Imfinzi, Tagrisso and Enhertu, and partner Daiichi Sankyo won European Commission approval for Enhertu as post-surgery treatment in HER2-positive early breast cancer, the company said Tuesday in a Form 6-K. The approval triggers a $75 million milestone payment from AstraZeneca to Daiichi Sankyo.

A 53% cut in recurrence risk

The approval covers Enhertu (trastuzumab deruxtecan) as a single-drug adjuvant treatment, meaning after surgery, for adults with resected HER2-positive breast cancer who still have residual invasive disease after neoadjuvant (pre-surgery) taxane-based and HER2-targeted treatment. The company called it the first EU approval of Enhertu in the curative-intent early breast cancer setting.

In the DESTINY-Breast05 late-stage trial, Enhertu reduced the risk of invasive disease recurrence or death by 53% against T-DM1, the previous standard of care in this setting. Three-year invasive disease-free survival was 92.4% with Enhertu versus 83.7% with T-DM1, and the company said no new safety concerns emerged.

The trial enrolled 1,635 patients and was presented at the 2025 European Society for Medical Oncology Congress before publication in The New England Journal of Medicine. Lead investigator Sibylle Loibl of the German Breast Group and Goethe University Medicine Frankfurt said the result "has the potential to change how we treat eligible patients in this setting." The approval follows a positive opinion from the European Medicines Agency's human-medicines committee.

Who pays, and who books the sales

Under the March 2019 collaboration, AstraZeneca owes Daiichi Sankyo the $75 million for this indication. Daiichi Sankyo recognises Enhertu sales in most EU territories. Daiichi Sankyo discovered the drug, and the two companies develop and sell it jointly.

Enhertu is already approved in more than 35 countries for this adjuvant use based on DESTINY-Breast05. AstraZeneca's U.S.-listed shares closed at $172.06 on Monday, giving the company a market value of $266.8 billion.

Dave Fredrickson, AstraZeneca's executive vice president for its oncology haematology unit, said the approval has the potential to set a new benchmark, with more than 92 per cent of patients alive and free of invasive disease at three years.

Sources

More on AstraZeneca

All AstraZeneca (AZN) coverage →